Aim: To determine the effectiveness of vaginal estrogen cream to improve the rate of satisfactory colposcopy and subsequent smear result in patients in a hypoestrogenic state and an abnormal Papanicolaou smear. To delineate between abnormal smears secondary to atrophy and inflammation from preneoplastic change and suggest an effective treatment strategy to deal with this challenging situation.

Methods: Patients with abnormal cervicovaginal smears who were in a low estrogen state (postmenopausal or amenorrheic postnatal) undergoing colposcopy were identified. All patients had an unsatisfactory colposcopy and were treated with vaginal estrogen cream twice per week for 6 weeks and underwent repeat colposcopy, smear and targeted biopsy where required.

Results: Fifty-four patients had an abnormal smear and were clinically in a low estrogen state, with four having previously had a hysterectomy. After 6 weeks of vaginal estrogen therapy, 32 out of 50 patients' colposcopic examinations were satisfactory. Also, 40 out of 54 patients' smears returned to normal after treatment. Of the 14 patients with persistent smear abnormalities, only three were diagnosed with true high-grade pre-invasive disease.

Conclusion: The use of vaginal estrogen cream for patients with smear abnormalities and a low estrogen status improves the satisfactory colposcopy rate and improves the accuracy of the prediction of true high-grade pre-invasive disease. This treatment may then reduce the number of patients that require definitive treatment for their screen-detected abnormalities in this patient population.

Download full-text PDF

Source
http://dx.doi.org/10.1111/jog.12545DOI Listing

Publication Analysis

Top Keywords

vaginal estrogen
20
estrogen cream
16
low estrogen
16
estrogen
9
abnormal cervicovaginal
8
unsatisfactory colposcopy
8
satisfactory colposcopy
8
patients abnormal
8
estrogen state
8
smear abnormalities
8

Similar Publications

International Urogynecology Consultation Chapter 3 Committee 1 - Pessary Management.

Int Urogynecol J

January 2025

Division of Health Services Research & Implementation Science, Southern California Permanente Medical Group, San Diego, CA, USA.

Introduction And Hypothesis: This manuscript is part of the International Urogynecological Consultation (IUC) on Pelvic Organ Prolapse (POP), Chapter 3, Committee 1 focusing on pessary management of POP.

Methods: A narrative review was conducted by an international, multi-disciplinary group of clinicians working in the field of pelvic health following a search of the literature using the MeSH terms "pelvic organ prolapse" OR "urogenital prolapse" OR "vaginal prolapse" OR "uterovaginal prolapse" AND "pessary" OR "support device" OR "intravaginal device." Relevant studies, as determined after review using the Covidence manuscript review platform, were included.

View Article and Find Full Text PDF

The Mark Cuban Cost Plus Drug Company Effect on Urogynecologic Drugs.

Urogynecology (Phila)

January 2025

From the Department of Urology, Atrium Health Wake Forest Baptist, Winston-Salem, NC.

Importance: The Mark Cuban Cost Plus Drug Company (ie, Cost Plus Drugs) is a service that makes generic drugs affordable. Cortese et al recently published the top 9 most commonly used oral medications in treatment of urologic conditions and showed that Cost Plus Drugs would have provided an estimated $1.29 billion reduction in 2020 costs if they replaced the Medicare prices.

View Article and Find Full Text PDF

Background/objectives: Both hyperandrogenism (HA) and vitamin D deficiency (VDD) can separately lead to impaired vascular reactivity and ovulatory dysfunction in fertile females. The aim was to examine the early interactions of these states in a rat model of PCOS.

Methods: Four-week-old adolescent female rats were divided into four groups: vitamin D (VD)-supplemented ( = 12); VD-supplemented and testosterone-treated ( = 12); VDD- ( = 11) and VDD-and-testosterone-treated ( = 11).

View Article and Find Full Text PDF

Reproduction control in a feral feline population using an anti-GnRH vaccine.

Theriogenology

January 2025

Instituto de Investigaciones en Reproducción Animal, FCV, UNLP, Calle 60 y 118, La Plata, B1900AVW, Buenos Aires, Argentina; Universidad del Chaco Austral, Argentina. Electronic address:

This study aimed to evaluate the use of the Improvac® vaccine to avoid heat and pregnancies in queens and fertility in males during the breeding season. Twenty-eight intact animals were divided into treated males (G1, n = 7), treated females (G2, n = 18), and untreated males (G3, n = 3) that were untamed and could not be captured for immunization. In cats from the G1 group, the testicular volume (337.

View Article and Find Full Text PDF

Importance: Endocrine treatments, such as Tamoxifen (TAM) and/or Aromatase inhibitors (AI), are the adjuvant therapy of choice for hormone-receptor positive breast cancer. These agents are associated with menopausal symptoms, adversely affecting drug compliance. Topical estrogen (TE) has been proposed for symptom management, given its' local application and presumed reduced bioavailability, however its oncological safety remains uncertain.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!